Zenocutuzumab Production Cost Reports

The report provides a detailed analysis essential for establishing a Zenocutuzumab manufacturing plant. It encompasses all critical aspects necessary for Zenocutuzumab production, including the cost of Zenocutuzumab production, Zenocutuzumab plant cost, Zenocutuzumab production costs, and the overall Zenocutuzumab manufacturing plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Zenocutuzumab production plant. These encompass manufacturing processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Zenocutuzumab is an antibody that is used in the treatment of tumors. It uses the dock and block mechanism and works by blocking the interaction between two proteins, HER2 and HER3, preventing signals that promote tumor growth and survival, particularly in cancers with specific genetic changes. It is used for managing non-small cell lung cancer (NSCLC) and pancreatic ductal. It shows response rates of 34% in NSCLC and 42% in pancreatic cancer. It is studied for its usage in other tumors, including pancreatic and other types of cancers.

The market for Zenocutuzumab is driven by several factors. Its use for the treatment of patients with non-small cell lung cancer contributes to its growing demand. Its good response rate for the treatment of complex-to-treat cancers, as well as NSCLC and pancreatic cancer, make it a sought-after product. The demand for significant medical need for compounds specifically targeting NRG1 fusion-positive tumors makes it a sought-after product. Its possible use in combination therapies further contributes to its demand.  Thus, industrial Zenocutuzumab procurement is influenced by its ability to treat non-small cell lung cancer (NSCLC) and pancreatic cancer, particularly for patients with NRG1 fusion-positive tumors, along with good response rates and use in combination therapies.

Raw Material for Zenocutuzumab Production

According to the Zenocutuzumab manufacturing plant project report, the key raw materials used in the production of Zenocutuzumab include CHO-K1 Cells-Plasmids-Buffers.

Manufacturing Process of Zenocutuzumab

The extensive Zenocutuzumab production cost report consists of the following major industrial manufacturing process:

1. From CHO-K1 Cells, Plasmids, and Buffers: The manufacturing of Zenocutuzumab consists of several steps. First, a stable CHO-K1 cell line is transfected with plasmids encoding the antibody chains. The process involves two strategies for introducing genetic material into cells to optimize gene expression. It is cultured in a bioreactor for about 14 days forming. The supernatant is then purified using chromatography to get pure Zenocutuzumab. CHO-K1 cells, plasmids, selective media, chromatography resins, and formulation buffers.

Zenocutuzumab is a clear to slightly opalescent liquid solution. Its molecular weight for heavy chains is around 50 kDa, and for the light chain is about 25 kDa.  It is formulated at a concentration of 20 mg/mL and stored at 2-8°C for long-term stability. It has improved antibody-dependent cell-mediated cytotoxicity activity. Its overall response rate is between 27% to 37.2%, and clinical benefit rates are around 49% to 61.5%. Its half-life is around 117 hours and it employs a unique mechanism of dock and block. All these physical and chemical properties make it a promising therapeutic option in oncology.